Hemagglutinating virus of Japan envelope (HVJ-E) vector with inactivated replication-defective Sendai virus was originally developed as a versatile drug delivery system. Recently, we have shown the direct tumor-killing activity of HVJ-E itself without therapeutic molecules in prostate cancer cells. Although human glioblastoma cells were also sensitive to HVJ-E treatment, complete eradication was not achieved using HVJ-E alone. Here, to develop more effective therapeutic strategy of glioblastoma, we enhanced the anti-tumor activity by incorporating Short interfering RNA (siRNA) of mitotic motor protein Eg5 into HVJ-E. Treatment with HVJ-E-containing Eg5 siRNA induced monopolar spindle formation and resulted in cell-cycle arrest and apoptosis. When HVJ-E-containing Eg5 siRNA was directly injected into an intradermal tumor xenograft, all mice became tumor-free. Similar results were observed in the intracranial tumor xenografts. The survival time of treated mice was significantly prolonged when HVJ-E was used. Histological examination showed that tumors remained in the brain after treatment with HVJ-E-containing negative control siRNA, but no tumors were detected after treatment with HVJ-E-containing Eg5 siRNA. This remarkable anti-tumor response was likely due to a synergistic effect of Eg5 siRNA and HVJ-E. Thus, this combination shows promise as an attractive novel therapy for glioblastoma.
Introduction
Glioblastoma is the most malignant primary brain tumor in adults. The prognosis of glioblastoma is generally extremely poor, with a median survival time of o15 months. 1 In spite of advances in surgery, chemotherapy and radiotherapy over the past three decades, there has been no change in survival rates, 2, 3 emphasizing a critical need to develop novel therapeutic approaches for this disease. This unfavorable prognosis is mainly because of its high propensity for tumor recurrence. It has been suggested that glioblastoma recurrence is inevitable after a median survival time of 8-9 months. 4 When patients with glioblastoma develop recurrence, most available treatment options have a limited effect on the overall outcome. Complete eradication of tumor cells should be developed to suppress tumor recurrence.
Inhibition of the mitotic spindle has been identified as an attractive target in cancer treatment.
5 Eg5 (also known as Kinesin-5 and Kif11) is a plus-end-directed mitotic motor protein of the BimC kinesin superfamily that has an important role in the early stages of mitosis. It mediates centrosome separation and formation of the bipolar mitotic spindle, 6 and cross-links and slides microtubules in relation to one another using energy from ATP hydrolysis. 7 Inhibition of Eg5 leads to a mitotic arrest with monopolar microtubule structures and ultimately to apoptosis. 5, 8 In contrast to microtubule inhibitors (taxanes and vinca alkaloids), which perturb tubulin polymerization/depolymerization, Eg5 inhibition does not interfere with the essential intracellular functions of microtubules. 9 Therefore, Eg5 inhibition does not cause the severe side effects that frequently accompany the use of microtubule inhibitors. 10 The first identified Eg5 inhibitor was monastrol; 11 many other Eg5 inhibitors have subsequently been identified. [12] [13] [14] [15] [16] [17] The monastrol analogs enastron, dimethylenastron and vasastrol showed antiproliferative effects on glioblastoma cell lines in vitro, 18 and the Eg5 antisense oligonucleotide showed antiproliferative effects on glioblastoma cell lines in vitro and in vivo. 19 Short interfering RNA (siRNA) has been evaluated as an attractive and effective tool for the inhibition of gene expression through specific degradation of mRNA. 20, 21 siRNA is superior to antisense oligonucleotides and ribozymes in terms of efficiency and specificity. 22, 23 However, the application of siRNA is severely limited by its low transfection efficiency and poor tissue penetration in vivo. 24 We have developed a hemagglutinating virus of Japan envelope (HVJ-E) using inactivated Sendai virus, as a nonviral vector for drug delivery. [25] [26] [27] It can deliver siRNA, DNA, proteins and anti-cancer drugs into cells both in vitro and in vivo. 25, 28, 29 We reported previously that HVJ-E itself has a strong anti-tumor effect against mouse tumors, such as colon carcinoma and renal carcinoma, by the activation of cytotoxic T lymphocytes and natural killer cells. 30, 31 However, even in either severe combined immunodeficiency (SCID) or NOD-SCID mice, tumor-suppression was observed after HVJ-E treatment. Recently, we have reported the direct tumor-killing activity of HVJ-E through induction of type I interferon on hormone-resistant human prostate cancer cells. 32 Human glioblastoma cells were also sensitive to HVJ-E alone without therapeutic molecules. However, complete eradication was not achieved by HVJ-E alone in glioblastoma-bearing mice. To develop more effective anti-tumor strategy to glioblastoma, we report the combination therapy of Eg5 siRNA and HVJ-E.
Results
HVJ-E-containing Eg5 siRNA induced knock down of Eg5 and suppression of viability in human glioblastoma cells
We have already reported that HVJ-E can deliver siRNA and DNA into various cell lines. 25 First, we ascertained that HVJ-E could deliver genes into human glioblastoma cells. We administered HVJ-E-containing FITC-ODN into A-172 glioblastoma cells: the green fluorescence-labeled ODN was delivered into approximately 95% of the cells ( Figure 1a) . Next, Eg5 siRNA was delivered to human glioblastoma cells using HVJ-E. When we used Eg5 siRNA (#AM4639, Applied Biosystems), western blot analysis showed the level of Eg5 protein to be approximately 18% of that in untreated A-172 cells and 39% of that in untreated U-118MG cells (Figure 1b) . The suppression rate by other Eg5 siRNAs was lower than that of Eg5 siRNA (#AM4639) (Figure 1b) . Most of the human glioblastoma cell lines showed sensitivity to HVJ-E itself, which was confirmed by the formation of fused cells, especially in T98G cells; sensitivity was relatively low in A-172 and U-118MG cells. When we treated human glioblastoma cells with HVJ-E-containing Eg5 siRNA, their viability was significantly suppressed (Figure 1c) , with the largest effects of Eg5 siRNA being observed in the A-172 and U-118MG cell lines in comparison with the effect of negative control siRNA. Furthermore, other Eg5 siRNAs such as Eg5-1, Eg5-2 and Eg5-3 hardly affected cell viability (Figure 1c) , so we decided to use Eg5 siRNA (#AM4639) for the rest of the study.
HVJ-E-containing Eg5 siRNA arrested the cell cycle by interference with bipolar spindle formation, and induced apoptosis
To confirm that the enhanced antiproliferative activity of HVJ-E-containing Eg5 siRNA was reflected in its antimitotic activity, we examined cellular microtubules and DNA by immunofluorescence microscopy in A-172 glioblastoma cells. Untreated control cells and cells treated with HVJ-E-containing negative control siRNA showed a typical bipolar mitotic spindle, in contrast, cells treated with HVJ-E-containing Eg5 siRNA showed a monopolar spindle formation (Figure 2a) . We then analyzed the result of disrupted bipolar spindle formation on cell-cycle progression by flow cytometric analysis for DNA content. We found that treatment with HVJ-Econtaining Eg5 siRNA induced a marked G2/M cellcycle block. In particular, at 24 h, 28.5 ± 1.3% of cells treated with HVJ-E-containing Eg5 siRNA were found to be blocked in the G2/M phase, compared with 16.6 ± 1.3% of untreated control cells. We also found that treatment with HVJ-E-containing Eg5 siRNA induced apoptosis, as revealed by a marked increase of cells with sub-G1 DNA content at 48 h (Figure 2b ). To examine in detail the possibility of apoptotic cell death caused by HVJ-E-containing Eg5 siRNA, we carried out terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay after the treatment. Abundant apoptotic cells were detected 24 h after treatment with HVJ-E-containing Eg5 siRNA in A-172 glioblastoma cells, whereas only a small number of apoptotic cells were detected after treatment with HVJ-E or HVJ-Econtaining negative control siRNA ( Figure 3a) . Next, to evaluate quantitatively the degree of apoptosis, we carried out the annexin V staining assay after treatment. In A-172 glioblastoma cells, 10.6±1.6% of cells treated with HVJ-E-containing Eg5 siRNA and 7.3 ± 1.9% of those treated with HVJ-E-containing negative control siRNA were annexin V-positive. The difference in the number of apoptotic cells was statistically significant (Po0.05). Following this, we carried out western blot analysis for caspase-3 and poly ADP-ribose polymerase, which are converted from the inactive pro-form into the active cleaved form during apoptosis. Treatment with HVJ-E-containing Eg5 siRNA led to increase in both caspase-3 and poly ADP-ribose polymerase cleavage (Figure 3b) , and similar results were observed in U-118MG glioblastoma cells (data not shown).
HVJ-E-containing Eg5 siRNA showed an anti-tumor effect against intradermal tumor xenografts of human glioblastoma
The implanted A-172 cells did not grow intradermally or subcutaneously in SCID mice, so it was necessary to use U-118MG cells for in vivo experiments. We examined the efficacy of intratumoral injections of HVJ-E-containing Eg5 siRNA to suppress tumor growth. First, to confirm siRNA delivery into the tumor cells, tumor tissues were harvested from the mice. Western blot analysis showed the level of Eg5 protein in tumor tissues treated with HVJ-E-containing Eg5 siRNA to be approximately 17% of that in untreated tumor tissues (Figure 4a ). Immunofluorescence of tumor tissues revealed the tumor cells treated with HVJ-E-containing Eg5 siRNA to show monopolar spindle formation (Figure 4b ).
We then examined whether HVJ-E-containing Eg5 siRNA induced apoptosis in intradermal tumors. Consistent with our results from apoptotic assays in cultured cells, abundant apoptotic cells were detected in tumor tissue by TUNEL assay 24 h after treatment with HVJ-Econtaining Eg5 siRNA (Figure 5a ). Western blot analysis also showed that treatment with HVJ-E-containing Eg5 siRNA led to caspase-3 activation (Figure 5b) .
Next, we investigated tumor growth after three injections with HVJ-E-containing Eg5 siRNA, HVJ-Econtaining negative control siRNA, HVJ-E or phosphatebuffered saline (PBS). Injection with HVJ-E-containing Eg5 siRNA led to the eradication of all tumors, whereas no eradication was observed after injection with the other agents. Treatment with HVJ-E-containing Eg5 siRNA significantly inhibited the growth of tumors compared with the other treatment groups (Figure 6 ). 
HVJ-E-containing Eg5 siRNA showed anti-tumor effect against intracranial tumor xenografts of human glioblastoma
To evaluate the therapeutic efficacy of HVJ-E-containing Eg5 siRNA, we also studied intracranial U-118MG glioblastoma xenograft models. U-118MG glioblastoma cells were stereotactically inoculated into the brains of mice: 21 days after inoculation, HVJ-E-containing Eg5 siRNA, HVJ-E-containing negative control siRNA or PBS was injected into the tumor sites. Tumor production was confirmed by H&E staining of the coronal sections of brains used for TUNEL assay on day 22. The tumors were localized with relatively clear boundaries, and the long and short axes were 1689.4 ± 91.2 and 991.3±220.5 mm (n ¼ 3), respectively, which were measured in the coronal section showing the maximal area of each tumor. There were no signs of drug toxicity, such as weight loss (data not shown). We carried out the TUNEL assay using brain sections harvested 24 h after treatment. Abundant apoptotic cells were detected from tumor tissues treated with HVJ-E-containing Eg5 siRNA, whereas few apoptotic cells were detected from surrounding normal brain tissues (Figure 7a ). Furthermore, when HVJ-E-containing Eg5 siRNA was directly injected into normal brain tissue, no apoptotic cells were observed ( Figure 7b ). All mice treated with PBS died by day 80 after tumor inoculation. The survival time of treated mice was significantly prolonged when HVJ-E was used (Figure 8a ). On day 90, intracranial tumors in all surviving mice treated with HVJ-E-containing Eg5 siRNA were completely eradicated, whereas no eradication were observed in surviving mice treated with HVJ-E-containing negative control siRNA (Figure 8b ). One mouse treated with HVJ-E-containing Eg5 siRNA died on day 67 because of tumor growth: thus, injection with HVJ-E-containing Eg5 siRNA led to the eradication of 80% of intracranial tumors.
Discussion
This study showed that treatment with HVJ-E-containing Eg5 siRNA induced tumor-cell apoptosis resulting in eradication or growth inhibition of human glioblastoma xenografts in mice. Anti-tumor effects were observed after treatment with HVJ-E alone, but further tumor suppression was shown by incorporating Eg5 siRNA. Glioblastoma, like many non-neural solid cancers, mostly comprises actively proliferating cells. Of several well-known molecular targets, inhibition of the mitotic spindle has been identified as an attractive target in cancer treatment. Vincristine, a microtubule inhibitor, has been approved for glioma and has widely been used in the clinic in combination with other chemotherapeutic agents. 33 Similar to microtubule inhibitors, Eg5 inhibition leads to mitotic arrest and apoptosis. 5, 8 It was reported that Eg5 inhibition activated Bax and caspase-3 via the intrinsic apoptotic pathway independently of p53. 34 In contrast to microtubule inhibitors, which perturb tubulin polymerization/depolymerization, Eg5 inhibition does not directly interfere with the essential intracellular functions of microtubules. 9 Here, Eg5 inhibition induced a monopolar spindle formation (Figure 2a ) and G2/M cell-cycle block (Figures 2b and c) and resulted in apoptotic cell death (Figure 3 ). However, we observed no effects on interphase microtubules (data not shown). These results suggest that Eg5 inhibition might evade serious side effects especially in neuronal cells, sparing the essential cytoskeletal function of microtubules. Several studies have previously demonstrated Eg5 15, 18, [35] [36] [37] A tumor growth inhibitory effect of Eg5 antisense oligonucleotide against subcutaneous tumors of human glioblastoma in mice has been reported; however, no eradication of the tumors was observed. 19 Thus, we reasoned that Eg5 inhibition would be an attractive candidate for developing a novel approach for the treatment of glioblastoma.
We have previously reported that HVJ-E introduced strong anti-tumor immune responses in tumor-bearing mice following direct intratumoral injection. 30, 31 HVJ-E activates cytotoxic T lymphocytes by enhancing effector T cell-mediated immunity and inhibiting regulatory T cell-mediated immunosuppression through interleukin-6 secretion from maturated dendritic cells. 30 HVJ-E also promotes natural killer cell migration by enhancing CXCR10 expression, and activates natural killer cells through dendritic-cell maturation. 31 However, even in either SCID or NOD-SCID mice, tumor suppression was observed after HVJ-E treatment. Recently, we have reported the direct tumor-killing activity of HVJ-E through induction of type I interferon on hormoneresistant human prostate cancer cells. 32 Introduced type I interferon enhanced caspase-8 expression via the JAK-STAT pathway, activated caspase-3 and induced apoptosis in cancer cells. Here, we have demonstrated the direct tumor-killing activity of HVJ-E on human glioblastoma cells. However, different human glioblastoma cell lines exhibited different degrees of sensitivity to HVJ-E itself: the viability of T98G cells was vigorously suppressed, whereas the effect on A-172 and U-118MG cells was limited. Therefore, we attempted to enhance the anti-tumor activity of HVJ-E by incorporating therapeutic molecules. HVJ-E was originally developed as a delivery vector, 25 and can incorporate and deliver siRNA, DNA, proteins and anti-cancer drugs into cells both in vitro and in vivo. 25, 28, 29 Delivering Rad51 siRNA using HVJ-E into cancer cells enhanced their sensitivity to CDDP. 28 The most important finding of the present study was that treatment with HVJ-E-containing Eg5 siRNA led to Combination therapy of HVJ envelope with Eg5 siRNA M Matsuda et al complete eradication of all of the intradermal U-118MG tumors and approximately 80% of intracranial U-118MG tumors, whereas no eradication of tumors was obtained by treatment with either HVJ-E alone or HVJ-E-containing negative control siRNA. This fact suggests that combination therapy of Eg5 siRNA and HVJ-E may suppress the recurrence of glioblastoma. To deliver siRNA into all the cells within a tumor mass is impossible, and even when HVJ-E was used, the efficiency of a single siRNA injection into a tumor was only 50%. 28 Transfection of Eg5 siRNA led to apoptosis of efficiently delivered tumor cells and the remaining cells were killed by HVJ-E through direct tumor-killing activity by the induction of type I interferon and antitumor immunity by the activation of natural killer cells as previously reported. Combination therapy of HVJ envelope with Eg5 siRNA M Matsuda et al
As this experiment was carried out using SCID mice, activation of cytotoxic T lymphocytes was not reflected in this remarkable anti-tumor response. Further advantage with activated cytotoxic T lymphocytes will be expected in the clinic. Although in this study, we used direct injection of HVJ-E into the tumor mass, systemic administration will be desirable in the future. We have already developed the technology for constructing a tissue-targeting HVJ-E from modification of fusion proteins with targeting molecules by genetic engineering. 38 To increase the targeting specificity and decrease hemagglutination, we have also developed the technology to establish hemagglutinin-neuraminidase (HN)-depleted HVJ-E using HN-specific siRNA. 39 By combining these two technologies, tumor-targeting HVJ-E has been prepared. 40 Antibodies specific to glioblastomaassociated cell surface receptors such as interleukin-13 receptor a2 subunit (IL13Ra2) and epidermal growth factor receptor variant III (EGFRvIII) 41, 42 may be useful for constructing glioblastoma-targeting HVJ-E based on our technologies. The glioblastoma-targeting HVJ-E will be applied to treat patients with disseminated glioblastoma after strict safety tests in non-human primates.
In summary, we have demonstrated that HVJ-Econtaining Eg5 siRNA shows vigorous anti-tumor activity against human glioblastoma xenografts, resulting in tumor eradication. This combination therapy should provide an attractive novel approach for the treatment of glioblastoma. To confirm its usefulness for human glioblastoma, clinical trials using a clinical grade HVJ-E 43 are warranted.
Materials and methods

Cell lines and mice
Human A-172, T98G and U-118MG glioblastoma cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). T98G was maintained in minimum essential medium (MEM) (Gibco-BRL, Rockville, MD, USA) and A-172 and U-118MG were maintained in Dulbecco's modified Eagle's medium (DMEM) (Nacalai Tesque, Kyoto, Japan). Both MEM and DMEM were supplemented with 10% fetal bovine serum (FBS) (Biowest, Nuaillé, France), 100 U ml À1 penicillin and 0.1 mg ml À1 streptomycin (penicillin-streptomycin Mixed Solution) (Nacalai Tesque). Cells were incubated at 37 1C in a humidified atmosphere of 95% air and 5% CO 2 . Female CB-17/ IcrCrj-SCID mice aged 5-6 weeks were purchased from Japan Clea (Tokyo, Japan) and were maintained in a temperature-controlled, pathogen-free room. All animals were handled according to the approved protocols and the guidelines of the Animal Committee of Osaka University.
Preparation of HVJ-E
Hemagglutinating virus of Japan (VR-105 parainfluenza1 Sendai/52, Z strain) was purchased from ATCC, amplified in the chorioallantoic fluid of 10-14-day-old chick eggs, purified by centrifugation, and inactivated by exposure to UV irradiation (99 mJ cm À2 ) as previously described. 25 Inactivated virus cannot replicate, but its capacity for viral fusion remains.
HVJ-E vector-mediated siRNA transfection in vitro
At first, three different siRNA-targeting Eg5 mRNAs were designed as follows:
0 -GGGCGUACAAGAACAUCU ATT-3 0 (Eg5-2) and 5 0 -GGGUUACAGAGUUGUUUA UTT-3 0 (Eg5-3). Eg5-1 was designed as previously described; 44 Eg5-2 and Eg5-3 were designed by Mitsubishi Space Software (Tokyo, Japan). In addition, we used commercially available Eg5 siRNA (#AM4639; Applied Biosystems, Foster City, CA, USA), the sequence of which is not announced. HVJ-E prepared as above was suspended in PBS (3 Â 10 10 particles ml À1 ). In all, 10 ml of suspension (3 Â 10 8 particles) was mixed with 2 ml of 50 mM Eg5 siRNA solution, 4.5 ml of 3% Triton X-100 (final 0.2%), 3 ml of protamine sulfate (5 mg ml
À1
; Nacalai Tesque) and 58 ml of PBS, as previously described with slight modifications. 25, 28, 29 Negative control siRNA solution (#AM4635; Applied Biosystems) was used as a control. After 5 min of incubation at 4 1C, the suspension was centrifuged (18 500 g) for 5 min at 4 1C. After this, the pellet was washed twice with 500 ml PBS to completely remove the detergent and any unincorporated siRNA. For in vitro transfection of HVJ-E-containing siRNA, 1 Â 10 5 glioblastoma cells were seeded in 6-well plates 1 day before transfection. The HVJ-E-containing siRNA was suspended in 20 ml PBS and this suspension (3 Â 10 8 particles) was added to each well. The incorporation rate of siRNA was approximately 20% of total siRNA initially used 28 and approximately 20 pmol siRNA were delivered to 1 Â 10 5 cells. Combination
Western blot analysis
Eg5 protein levels and caspase-3 activation were determined by western blot analysis. The harvested cells were lysed in lysis buffer 24 h after transfection. After adding the same amount of sample buffer, the cell lysates were boiled for 5 min. Protein (10 mg) from each cell lysate was electrophoresed on 5-20% sodium dodecyl sulfate polyacrylamide gel. After transfer onto a polyvinylidene fluoride membrane, the membrane was incubated for 1 h with blocking buffer (5% skim milk (Nacalai Tesque) in wash buffer (2 
Cell proliferation assay
Cell survival was assessed 48 h after treatment, with CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) according to the manufacturer's instructions.
Immunofluorescence
To visualize microtubules, 24 h after treatment, cells grown on polylysine/fibronectin-coated glass coverslips or tissue sections were fixed with methanol for 5 min at À20 1C and then washed with PBS. Nonspecific sites were blocked by incubating with 2% bovine serum albumin in PBS for 15 min. Cells were incubated with FITC-conjugated anti-a-tubulin antibody (1:100 dilution, Sigma, St Louis, MO, USA) at 37 1C for 1 h. The nuclei were stained with DAPI (4 0 ,6-diamidino-2-phenylindole; Sigma) for 5 min. Coverslips were mounted with VECTASHIELD mounting medium (Vector Laboratories, Burlingame, CA, USA) and imaged with a confocal laser microscope (Radiance 2100; Bio-Rad Japan, Tokyo, Japan) equipped with Laser Sharp 2000 software.
Cell-cycle analysis
Progression of the cell cycle was analyzed by flow cytometry. Cells were washed twice with PBS then fixed Combination therapy of HVJ envelope with Eg5 siRNA M Matsuda et al in 70% ice-cold ethanol overnight at À20 1C. Next, the cells were washed twice with PBS, treated with propydium iodide/RNase staining buffer (BD Biosciences, San Diego, CA, USA) using 0.5 ml per test (1 Â 10 6 cells), and incubated for 15 min at room temperature. Analysis was done on a FACScan flow cytometer (Becton Dickinson, Sparks, MD, USA).
TUNEL assay for identifying DNA fragmentation in apoptotic cells
Apoptotic cells were detected 24 h after treatment. Cells grown on polylysine/fibronectin-coated glass coverslips or tissue sections were washed twice with PBS, and fixed with 4% paraformaldehyde for 15 min at 4 1C. The TUNEL assay was carried out using the in situ Apoptosis Detection Kit (TAKARA Bio, Shiga, Japan) according to the manufacturer's instructions.
Annexin V staining assay
An annexin V staining assay was used 24 h after treatment to determine the percentage of apoptotic cells. The annexin V staining assay was carried out by using the annexin V-FITC apoptosis detection kit (BD Biosciences) according to the manufacturer's instructions. Briefly, the treated cells were washed with PBS then resuspended in binding buffer. The cells were incubated with FITC-conjugated annexin V and propydium iodide for 15 min in the dark at room temperature. After this, the stained cells were analyzed on a FACScan flow cytometer.
Intradermal tumor model and tumor treatment
Mice were anesthetized with an inhalation of isoflurane. Viable 5 Â 10 6 U-118MG cells were re-suspended in 100 ml PBS and injected into the intradermal space in the backs of the mice. The inactivated HVJ-E suspension (6 Â 10 9 particles) was mixed with 40 ml of 50 mM Eg5 siRNA solution, 4.5 ml of 3% Triton X-100 (final 0.2%), 8 ml of protamine sulfate and 12 ml of PBS. The HVJ-E-containing siRNA was suspended in 100 ml PBS. When tumors had grown to approximately 6-8 mm in diameter (7 days after inoculation), the mice were randomly divided into four treatment groups to examine the treatment efficacy. On days 7, 10 and 13, 100 ml (6 Â 10 9 particles) of HVJ-Econtaining Eg5 siRNA or 100 ml of HVJ-E-containing negative control siRNA or 100 ml of HVJ-E alone, or 100 ml of PBS were injected into the tumor. Approximately 400 pmol siRNA were delivered to the tumor mass in a mouse. Tumor size was measured with slide calipers twice every week, and the tumor volume was calculated according to the following formula: tumor volume (mm 3 ) ¼ length Â (width) 2 /2. Mice treated with HVJ-E-containing Eg5 siRNA, HVJ-E-containing negative control siRNA or PBS on day 7 were killed 24 h after treatment, then tumor tissues were collected for the following assays. Tissues were lysed in lysis buffer and used for western blot analysis. Other collected tumor tissues were embedded in Tissue-Tek OCT compound (Sakura Finetek, Tokyo, Japan), frozen in dry ice, and then cut into 5 mm serial sections with a Cryostat (Leica Microsystems AG, Wetzlar, Germany). Tissue sections were used for immunofluorescence or TUNEL assay.
Intracranial tumor model and tumor treatment
Mice were anesthetized with an intraperitoneal injection of pentobarbital (60 mg kg
À1
) and placed in a stereotactic instrument for mice (SR-5M, Narishige, Tokyo). After scalp incision, a burr hole was drilled at the stereotactically defined location of the caudate/putamen (0.1 mm posterior to the bregma, 2.32 mm lateral to the midline). 45 Then 2 Â 10 6 U-118MG cells in 5 ml PBS were injected stereotactically over 3 min at a depth of 2.35 mm below the cortical surface using a sterile Hamilton syringe fitted with a 26-G needle. The needle was left in place for additional 2 min and then slowly withdrawn. Tumor-inoculated mice were randomly divided into three treatment groups (six animals each) to examine the treatment efficacy. Twenty-one days after inoculation, the mice were treated by injecting 5 ml (3 Â 10 9 particles) of HVJ-E-containing Eg5 siRNA or 5 ml of HVJ-Econtaining negative control siRNA, or 5 ml of PBS, into the tumor sites using the same coordinates on the Combination therapy of HVJ envelope with Eg5 siRNA M Matsuda et al stereotactic frame. Approximately 200 pmol siRNA were delivered to the tumor mass in a mouse. The survival times of 5 mice in each treatment group were recorded during 90 days after tumor inoculation. All surviving mice were killed on day 90 and the tumor growth was evaluated macroscopically and histologically. One mouse in each treatment group was killed 24 h after treatment. The mouse was transcardially perfused with 4% paraformaldehyde. The brain tissues were post-fixed overnight and serial coronal sections were taken from the injection site. Tissue sections were used for TUNEL assay and H&E staining.
Statistical analysis
For survival times, statistical analysis was carried out using the Kaplan-Meier method and the significance of differences with respect to the survival distribution was evaluated by the log-rank test. For the other studies, statistical analysis was carried out using the analysis of variance followed by Tukey's post hoc test or the Student's non-paired t-test. Po0.05 was considered statistically significant.
